Entera Bio Ltd. Average Days of Receivables

Average Days of Receivables of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Average Days of Receivables growth rates and interactive chart.


Highlights and Quick Summary

  • Annual Average Days of Receivables for 2019 was 429.96 (a -18.76% decrease from previous year)
  • Twelve month Average Days of Receivables ending June 29, 2020 was 0.0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Average Days of Receivables decreased by NaN% year-over-year
Trailing Average Days of Receivables for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 30 Dec '18
0.0 0.0 137.87 0.0
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Average Days of Receivables of Entera Bio Ltd.

Most recent Average Days of Receivablesof ENTX including historical data for past 10 years.

Interactive Chart of Average Days of Receivables of Entera Bio Ltd.

Entera Bio Ltd. Average Days of Receivables for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 429.96
2018 529.25

Business Profile of Entera Bio Ltd.

Sector: Medical
Industry: Drugs
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product includes the EB612, an oral parathyroid hormone product candidate that has completed a Phase IIa clinical trial for hypoparathyroidism. It is also developing EB613 that has completed Phase I clinical trials for the treatment of osteoporosis and non-union fractures. The company was founded in 2010 and is headquartered in Jerusalem, Israel.